317 related articles for article (PubMed ID: 27459659)
1. Nephrotoxic Medication Exposure in U.S. Adults with Predialysis Chronic Kidney Disease: Health Services Utilization and Cost Outcomes.
Davis-Ajami ML; Fink JC; Wu J
J Manag Care Spec Pharm; 2016 Aug; 22(8):959-68. PubMed ID: 27459659
[TBL] [Abstract][Full Text] [Related]
2. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
Pauly NJ; Brown JD
J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
[TBL] [Abstract][Full Text] [Related]
4. Impact of Depression on Health and Medical Care Utilization and Expenses in US Adults With Migraine: A Retrospective Cross Sectional Study.
Wu J; Davis-Ajami ML; Kevin Lu Z
Headache; 2016 Jul; 56(7):1147-60. PubMed ID: 27350407
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.
Daniel GW; Malone DC
J Manag Care Pharm; 2007 Mar; 13(2):142-54. PubMed ID: 17330975
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Healthcare Cost Savings of a Pediatric Nephrotoxic Medication-Associated Acute Kidney Injury Reduction Program in a Simulated Sample.
Dynan L; Lazear D; Goldstein SL
J Pharm Pract; 2023 Aug; 36(4):795-802. PubMed ID: 35343287
[No Abstract] [Full Text] [Related]
7. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
8. Unfilled Prescriptions of Medicare Beneficiaries: Prevalence, Reasons, and Types of Medicines Prescribed.
Kennedy J; Tuleu I; Mackay K
J Manag Care Spec Pharm; 2020 Aug; 26(8):935-942. PubMed ID: 32715958
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. A Payer Perspective of the Costs of Urinary Tract and Skin and Soft Tissue Infections in Adults with Diabetes and the Relationship to Oral Antidiabetic Medication Nonadherence.
Davis-Ajami ML; Pakyz A; Wu J; Baernholdt M
J Manag Care Spec Pharm; 2019 Dec; 25(12):1409-1419. PubMed ID: 31436479
[TBL] [Abstract][Full Text] [Related]
11. Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD.
Lefebvre CE; Filion KB; Reynier P; Platt RW; Zappitelli M
Clin J Am Soc Nephrol; 2020 Jan; 15(1):61-68. PubMed ID: 31831578
[TBL] [Abstract][Full Text] [Related]
12. Patterns of use and expenses associated with mail-service pharmacy in adults with diabetes.
Wu J; Davis-Ajami ML; Noxon V
J Am Pharm Assoc (2003); 2015; 55(1):41-51. PubMed ID: 25539092
[TBL] [Abstract][Full Text] [Related]
13. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
14. Differences in health services utilization and costs between antihypertensive medication users versus nonusers in adults with diabetes and concomitant hypertension from Medical Expenditure Panel Survey pooled years 2006 to 2009.
Davis-Ajami ML; Wu J; Fink JC
Value Health; 2014; 17(1):51-61. PubMed ID: 24438717
[TBL] [Abstract][Full Text] [Related]
15. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Opioid Use and Mental Illness on Chronic Disease Medication Adherence in Superutilizers.
Surbhi S; Graetz I; Wan JY; Gatwood J; Bailey JE
J Manag Care Spec Pharm; 2018 Mar; 24(3):198-207. PubMed ID: 29485952
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors.
Schreier DJ; Rule AD; Kashani KB; Mara KC; Kane-Gill SL; Lieske JC; Chamberlain AM; Barreto EF;
Am J Nephrol; 2022; 53(4):273-281. PubMed ID: 35294951
[TBL] [Abstract][Full Text] [Related]
18. Risk of chronic kidney disease in children who developed acute kidney injury secondary to nephrotoxic medication exposure in infancy.
Ameta P; Stoops C; Askenazi DJ
Ren Fail; 2023 Dec; 45(1):2218486. PubMed ID: 37254865
[TBL] [Abstract][Full Text] [Related]
19. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
